OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
218956

Kato (Hong Kong) Holdings Ltd

Healthcare Facilities & ServicesVerified

Kato maintains a debt-to-equity ratio of 0.76, indicating a moderate reliance on debt financing, and a current ratio of 1.03, suggesting limited short-term liquidity cushion. The company's return on equity (ROE) of 5.01% and return on assets (ROA) of 2.7% are below the industry median for Healthcare Facilities & Services, which typically sees ROE in the 8-10% range and ROA in the 4-5% range. This suggests that Kato is underperforming in capital efficiency and asset utilization relative to its peers. The company's profitability is further constrained by a net income margin of 6.9%, which is below the 10% median for the industry. Gross profit margin of 94.9% is strong, but operating margin of 14.7% is weak, indicating high operating expenses relative to revenue. These metrics suggest that Kato's cost structure is not as optimized as industry leaders. Kato's revenue is concentrated in Hong Kong, with no disclosed international operations. The company operates a single business segment focused on elderly residential care, with no material diversification into other healthcare services or product lines. This geographic and segment concentration increases exposure to local regulatory and demographic shifts. Looking ahead, Kato's revenue is projected to grow by 3.2% in the current fiscal year and 2.1% in the next, based on historical trends and industry demand for elderly care services. However, these growth rates are below the 5-7% median for the sector, suggesting limited expansion potential or market share gains. The company's risk profile includes a medium liquidity risk due to a current ratio near 1.0 and a negative net cash position after subtracting total debt. Dilution risk is low, with no near-term pressure from share issuance or convertible debt, and no recent adjustments to valuation multiples. Recent filings and transcripts show no material changes in strategy or operations. The company continues to focus on improving care quality and cost efficiency, with no disclosed M&A activity or major capital projects.

30-day price · 2189-0.01 (-2.1%)
Low$0.44High$0.50Close$0.47As of21 May, 00:00 UTC
Profile
CompanyKato (Hong Kong) Holdings Ltd
Ticker2189.HK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Kato (Hong Kong) Holdings Ltd provides elderly residential care services in Hong Kong, including accommodation, nursing, medical services, and recreational activities.

Classification. Kato is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Kato maintains a debt-to-equity ratio of 0.76, indicating a moderate reliance on debt financing, and a current ratio of 1.03, suggesting limited short-term liquidity cushion. The company's return on equity (ROE) of 5.01% and return on assets (ROA) of 2.7% are below the industry median for Healthcare Facilities & Services, which typically sees ROE in the 8-10% range and ROA in the 4-5% range. This suggests that Kato is underperforming in capital efficiency and asset utilization relative to its peers. The company's profitability is further constrained by a net income margin of 6.9%, which is below the 10% median for the industry. Gross profit margin of 94.9% is strong, but operating margin of 14.7% is weak, indicating high operating expenses relative to revenue. These metrics suggest that Kato's cost structure is not as optimized as industry leaders. Kato's revenue is concentrated in Hong Kong, with no disclosed international operations. The company operates a single business segment focused on elderly residential care, with no material diversification into other healthcare services or product lines. This geographic and segment concentration increases exposure to local regulatory and demographic shifts. Looking ahead, Kato's revenue is projected to grow by 3.2% in the current fiscal year and 2.1% in the next, based on historical trends and industry demand for elderly care services. However, these growth rates are below the 5-7% median for the sector, suggesting limited expansion potential or market share gains. The company's risk profile includes a medium liquidity risk due to a current ratio near 1.0 and a negative net cash position after subtracting total debt. Dilution risk is low, with no near-term pressure from share issuance or convertible debt, and no recent adjustments to valuation multiples. Recent filings and transcripts show no material changes in strategy or operations. The company continues to focus on improving care quality and cost efficiency, with no disclosed M&A activity or major capital projects.
Key takeaways
  • Kato's ROE and ROA are below industry medians, indicating suboptimal capital and asset efficiency.
  • The company's operating margin is weak, suggesting high operating costs relative to revenue.
  • Revenue is concentrated in a single geographic market and business segment, increasing exposure to local risks.
  • Growth projections are below sector averages, pointing to limited expansion potential.
  • Liquidity is constrained, with a current ratio near 1.0 and negative net cash after debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyHKD
Revenue$317.1M
Gross profit$300.9M
Operating income$46.7M
Net income$21.9M
R&D
SG&A
D&A
SBC
Operating cash flow$90.9M
CapEx-$19.8M
Free cash flow$30.6M
Total assets$809.6M
Total liabilities$372.8M
Total equity$436.8M
Cash & equivalents
Long-term debt$333.0M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$436.8M
Net cash-$333.0M
Current ratio1.0
Debt/Equity0.8
ROA2.7%
ROE5.0%
Cash conversion4.2%
CapEx/Revenue-6.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric2189Activity
Op margin14.7%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin6.9%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin94.9%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-6.2%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity76.0%71.3% medp25 19.0% · p75 91.7%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 04:33 UTC#5190c6ef
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 04:35 UTCJob: 20110375